Anti-mullerian hormone (AMH) neutralizing antibodies and uses thereof
The present invention relates to Anti-Mullerian Hormone (AMH) neutralizing antibodies and their use in the field of reproduction.
1. A method of improving folliculogenesis in a female subject comprising administering to the female subject a therapeutically effective amount of an Anti-Mullerian Hormone (AMH) neutralizing antibody which comprises a heavy chain comprising the H-CDR1, H-CDR2 and H-CDR3 of the heavy chain of the antibody obtainable from the hybridoma available under CNCM deposit number I-4965 and a light chain comprising the L-CDR1, L-CDR2 and L-CDR3 of the light chain of the antibody obtainable from the hybridoma available under CNCM deposit number I-4965.
2. The method of claim 1 , wherein the female subject has diminished ovarian reserve or responds poorly to controlled ovarian hyperstimulation.
3. The method of claim 1 which comprises the steps of i) determining the level of AMH in a blood sample obtained from the subject, ii) comparing the level determined at step i) with a predetermined reference value and iii) administering to the subject a therapeutically effective amount of the AMH neutralizing antibody when the level determined at step i) is higher than the predetermined reference value.
4. The method of claim 1 wherein the AMH neutralizing antibody comprises the heavy chain of the antibody obtainable from the hybridoma available under CNCM deposit number I-4965 and the light chain of the antibody obtainable from the hybridoma available under CNCM deposit number I-4965.
5. The method of claim 1 wherein the AMH neutralizing antibody is a murine antibody.
6. The method of claim 5 wherein the murine antibody is obtainable from the hybridoma available under CNCM deposit number I-4965.
7. The method of claim 1 wherein the AMH neutralizing antibody is a chimeric antibody.
8. The method of claim 7 wherein the chimeric antibody is a mouse/human antibody.
9. The method of claim 1 , wherein the AMH neutralizing antibody is a humanized antibody.
10. The method of claim 1 wherein the AMH neutralizing antibody is selected from the group of Fab, F(ab′)2, Fab′ and scFv.
11. The method of claim 1 , wherein the method is performed as an adjunct to controlled ovarian hyperstimulation (COH).
12. The method of claim 11 , wherein the controlled ovarian hyperstimulation comprises administration of a GnRH agonist or antagonist, recombinant follicle-stimulating hormone (FSH) or human Chorionic Gonadotropin (hCGH).
13. A method of treating polycystic ovary syndrome (PCOS) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an Anti-Mullerian Hormone (AMH) neutralizing antibody which comprises a heavy chain comprising the H-CDR1, H-CDR2 and H-CDR3 of the heavy chain of the antibody obtainable from the hybridoma available under CNCM deposit number I-4965 and a light chain comprising the L-CDR1, L-CDR2 and L-CDR3 of the light chain of the antibody obtainable from the hybridoma available under CNCM deposit number I-4965.